RI UFLA
metadata only
Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease
Introduction: Alzheimer’s disease (AD) is the most common cause of dementia. Clinical progress in this pathogenesis field has drawn the attention of researchers, stimulating the investigation of novel treatment methods. Current therapies that deal with cholinesterase inhibitors and/or NMDA antagonis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)#1125907
- A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease#857055
- Disease modifying treatments for Alzheimer's disease: Clinician perspectives.#159714
- Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease#981077
- Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers#1010091
Record · ID 1017073
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive